The inhibition of CYP2A6 by decursinol angelate, a pyranocoumarin isolated from Angelica gigas roots, was examined in human liver microsomes and recombinant CYP2A6. Decursinol angelate moderately inhibited coumarin 7-hydroxylation, but a 20-min preincubation with microsomes and NADPH significantly increased its inhibitory effect (IC 50 ; >20 versus 4.4 M). A similar inhibition pattern was observed in nicotine C oxidation, which is also one of the prototype reactions of CYP2A6. 
Cytochrome P450 (P450) 2A6, the major coumarin 7-hydroxylase present in human liver (Miles et al., 1990; Yun et al., 1991) , is known to metabolize a variety of compounds, including quinoline, nicotine, cotinine, aflatoxin B1, 2,6-dichlorobenzonitrile, and butadiene (Pelkonen et al., 2000) . CYP2A6 is one of the forms of P450 expressed in the human respiratory tract (Smith et al., 1995; Macé et al., 1998) , which is responsible for the metabolic activation of tobaccospecific nitrosamines, including 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (Tiano et al., 1994; Smith et al., 1995) , a potent pulmonary-specific carcinogen (Hecht, 1998) , to yield genotoxic metabolites. The expression of CYP2A6 is controlled by environmental and/or genetic factors (Oscarson, 2001; Paschke et al., 2001; Satarug et al., 2004 ). An individual's adverse response to exposure to CYP2A6 substrates, such as smoking, may depend on the level of CYP2A6 present in that individual. It seems that a lack of or reduced CYP2A6 activity might possibly lead to a decrease in tobacco-induced lung cancer risk. Therefore, the inhibition of CYP2A6 by dietary foods and/or supplements seems to be clinically important from the view of chemoprevention.
Decursinol angelate (Fig. 1 ), a pyranocoumarin, is one of major constituents in the dried roots of Angelica gigas Nakai (Konoshima et al., 1968; Ryu et al., 1990; Jung et al., 1991) , which has traditionally been used for the treatment of gynecological diseases, such as menoxenia and anemia, via its hemogenic, analgesic, and sedative activities in Korean herbal prescriptions (Chi and Kim, 1970) . Various herbal preparations containing Angelica radix are available over the counter not only in the Far Eastern countries but also in Western countries like United States, UK, and Germany. A. gigas roots have been used especially in Korea, and decursinol angelate is characterized as a main constituent of A. gigas roots (Konoshima et al., 1968; Ryu et al., 1990; Jung et al., 1991) . Decursinol angelate has been reported to have antioxidant (Lee et al., 2003a) and anti-tumor activities (Lee et al., 2003b) . Coumarin is a representative substrate for CYP2A6, and decursinol angelate can consequently serve as a substrate and/or inhibitor for CYP2A6 because of their structural similarities. This led us to investigate the effect of decursinol angelate on the activity of CYP2A6. In the present study, the effect of decursinol angelate on the CYP2A6 activity was investigated, and the decursinol angelate-induced inactivation of CYP2A6 in human liver microsomes and the recombinant CYP2A6.
Materials and Methods
Materials. The decursinol angelate was provided by Pharmacognosy Laboratory, Seoul National University (Seoul, Korea), with a chemical purity adjudged to be higher than 98% on the basis of HPLC chromatogram. Glucose 6-phosphate, ␤-NADP ϩ , glucose-6-phosphate dehydrogenase, coumarin, nicotine, cotinine, diclofenac, paclitaxel, phenacetin, mephenytoin, midazolam, terfenadine, glutathione (GSH) , N-acetylcysteine (NAC), methoxamine (MOA), catalase, and pilocarpine were purchased from Sigma Chemical Co. (St. Louis, MO). Dex-tromethorphan was purchased from Ultrafine (Manchester, UK). Human liver microsomes and the baculovirus-insect cell-expressed human CYP2A6 were purchased from BD Gentest (Woburn, MA). All other reagents used were of the highest commercially available grade. Recombinant human CYP2A6 for spectral analysis was expressed in Escherichia coli and purified as described previously (Soucek, 1999) .
Coumarin 7-Hydroxylase Assay. The incubation mixture consisted of 0.2 mg of human liver microsomes, decursinol angelate (1ϳ20 M), and 2.5 M coumarin, and an NADPH-generating system (0.1 M glucose 6-phosphate, 10 mg/ml ␤-NADP ϩ , and 1 U/ml glucose-6-phosphate dehydrogenase), in a total volume of 200 l of potassium phosphate buffer (0.1 M, pH 7.4). The reaction was initiated by the addition of the NADPH-generating system and continued in a water bath at 37°C. After incubation for 30 min, the reaction was stopped by the addition of 400 l of 0.1% acetic acid; 4 l of an internal standard solution (16 M terfenadine in methanol) was then added. The reaction solution was passed through activated Sep-Pak C 18 cartridges (96-well type OASIS HLB extraction cartridge; Waters, Milford, MA) and then washed twice with 1 ml of distilled water and eluted with 1 ml of methanol. The eluate was dried under a stream of nitrogen gas, the residue redissolved in 40 l of reconstitution buffer (0.1% formic acid/acetonitrile, 7:3), and a 10-l aliquot injected on to a C 18 column for LC/MS/MS analysis. The percent recoveries (%) for 7-OH-coumarin and terfenadine were measured to be 84.6 Ϯ 3.6 and 88.4 Ϯ 2.3%, respectively (n ϭ 3).
In addition, the effect of NADPH-dependent drug biotransformation on the extent of P450 inhibition was assessed. Decursinol angelate was preincubated for 20 min with an NADPH-generating system and human liver microsome and then further incubated for 30 min with a substrate mixture. Samples were treated and analyzed as described above.
Nicotine C-Oxidase Assay. To confirm the CYP2A6 inhibitory activity, effect of decursinol angelate on the nicotine C-oxidase activity was evaluated. The incubation mixture consisted of 0.2 mg of human liver microsomes, 0.6 mg of human liver cytosol, decursinol angelate (1ϳ20 M) and nicotine (50 M), and an NADPH-generating system, in a total volume of 200 l of potassium phosphate buffer (0.1 M, pH 7.4). The sample was treated and analyzed as described under Coumarin 7-Hydroxylase Assay. The percent recovery (%) for cotinine was measured to be 83.3 Ϯ 3.9 (n ϭ 3).
Inactivation Assay. To characterize the time-and concentration-dependent inhibition of the CYP2A6 activity by decursinol angelate, an inactivation assay was performed with human liver microsomes or cDNA-expressed CYP2A6 (with P450 reductase and cytochrome b 5 ). The human liver microsomes (2 mg of protein/ml) or cDNA-expressed CYP2A6 isozyme (0.5 mg of protein/ml) was incubated with various concentrations of decursinol angelate. The reaction mixture was preincubated at 37°C for 3 min prior to initiation of the reaction by the addition of an NADPH-generating system (1 mM of final concentration). After 0, 2, 5, 10, and 20 min of incubation, a 20-l aliquot of each incubation mixture was taken and added to a secondary reaction mixture containing 20 M coumarin and an NADPH-generating system in 0.1 M potassium phosphate buffer, pH 7.4, in a final volume of 200 l. The reaction was allowed to proceed for a further 30 min, and the 7-hydroxycoumarin formed in the reaction mixture determined by HPLC/MS/MS analysis. To investigate the effects of nucleophilic trapping agents, reactive oxygen species scavengers, or competitive inhibitor on the decursinol angelate-mediated inactivation of CYP2A6, inactivation assays were carried out with GSH, NAC, MOA, catalase, and pilocarpine in the same manner but for only one time point (20 min).
Partition Ratio Determination. The partition ratio for the CYP2A6 inactivation by decursinol angelate was estimated using the titration method (Silverman, 1996) . In brief, 0.2 M CYP2A6 enzyme was incubated for 30 min with various concentrations of decursinol angelate. As described under Inactivation Assay, a 20-l aliquot of each incubation mixture was taken and assayed for coumarin 7-hydroxylase activity. The turnover number (partition ratio ϩ1) was estimated by plotting the percentage of the activity remaining versus the molar ratio of decursinol angelate to CYP2A6, followed by regression of the linear portions of both the low and high ratios, with extrapolation of their intersection to the x-axis. Dialysis Experiments. The human liver microsomes (2 mg/ml) were incubated for 20 min with 20 M decursinol angelate in the presence or absence of NADPH. Samples were immediately placed in 6000 to 8000 molecular weight cutoff-dialysis tubing (Spectral Medical Industries, Los Angeles, CA) and dialyzed for 18 h at 4°C against 2000 ml of 0.1 M potassium phosphate buffer, pH 7.4, containing 5 mM EDTA. The protein content was subsequently measured, and the coumarin 7-hydroxylase assay was then performed.
HPLC/MS/MS. The HPLC system consisted of a LC-10ADvp binary pump system, with an API2000 triple quadrupole mass spectrometer (Applied Biosystems-SCIEX, Concord, ON, Canada), equipped with a TurboIonSpray source. Chromatographic separation was achieved on a C 18 Xterra column (2.1 ϫ 50 mm, 3.5 m). The HPLC mobile phases consisted of 0.1% formic acid (A) and acetonitrile (B). A linear gradient program was used from 5 to 90% solvent (B) for 4 min, following a 2-min re-equilibration. Electrospray ionization (ESI) was performed in the positive mode. Nitrogen was used as the nebulizing, turbo spray, and curtain gas, with the optimum values set at 40, 80, and 40 (arbitrary units), respectively. Multiple reaction monitoring detection was used for the detection of the P450 isozyme-specific marker metabolites. The precursor-product ion pairs used for monitoring the metabolites generated by CYP2A6 were: 1633107 (7-OH-coumarin), 177380 (cotinine), and 4723436 (IS, terfenadine).
Spectral Analysis. The P450 content was determined using a CO difference spectrum assay. Incubation mixtures, containing purified CYP2A6 isozyme (1 M), an NADPH-generating system, and either decursinol angelate (5 and 20 M) or dimethyl sulfoxide (25 M) in 0.1 M potassium phosphate buffer (pH 7.4), were incubated at 37°C for 10 and 20 min, respectively. After incubation, the incubation mixture was transferred to an ice bath, and then the P450 content was analyzed using a JASCO V-550 UV/VIS spectrophotometer (Jasco, Tokyo, Japan) using an established method (Omura and Sato, 1964) .
Metabolite Identification. Decursinol angelate (20 M) were incubated with cDNA-expressed CYP2A6 isozyme and NADPH-generating system for 1 h. After the sample preparation procedure, as described in the P450 probe substrate assay, the sample was analyzed using an LC/ESI/ion-trap mass spectrometer (HP1100 LC/MSD trap; Agilent Technologies, Palo Alto, CA). The chromatographic separation of decursinol angelate and metabolites was achieved on a YMC C 18 column (2 ϫ 150 mm, 5 m) using a gradient program. The mobile phases consisted of 0.1% formic acid (A) and acetonitrile (B). The solvent flow through the column was 0.2 ml/min, with initial condition of 80% A and 20% B, ramped linearly to 80% B over 18 min, and then returned to the initial conditions. The entire column eluent was directly introduced into a diode array detector and the ion-trap mass spectrometer with an ESI interface. Nitrogen was used as both the nebulizing and dying gas at 35 psi and at a flow rate of 8 l/min, respectively, at a temperature of 350°C. The mass spectrometer was operated in the positive ion mode, with a compound stability value of 80%. Helium was used as the collision gas for the MS/MS experiments. Fragmentation was induced with a resonant excitation amplitude of 0.85 to 1.00 V, following isolation of the desired precursor ion over a selected mass window of 1 Da. The structures of the decursinol angelate metabolites were characterized on the basis of their product ion mass spectra obtained under collision-induced dissociation ion trap mass spectrometry.
Trapping of Reactive Intermediate of Decursinol Angelate. Decursinol angelate (20 M) was incubated for 1 h with cDNA-expressed CYP2A6 isozyme, 1 mg/ml rat liver cytosol, 5 mM GSH, and an NADPH-generating system. The samples were prepared and analyzed using a constant neutral loss scan of m/z 129 by LC/ESI/ion-trap mass spectrometry. The LC/MS conditions were as described above, under Metabolite Identification. 
Results
Inhibition of CYP2A6 Activity. Decursinol angelate was evaluated for its CYP2A6 inhibitory activity in human liver microsomes. The CYP2A6 inhibitory activity was measured, with or without preincubation, using a marker substrate, coumarin. Decursinol angelate slightly inhibited the CYP2A6-mediated coumarin 7-hydroxylase activity with the IC 50 of Ͼ20 M but significantly inhibited the reaction with the IC 50 value of 4.4 M when preincubated for 20 min in the presence of NADPH (Fig. 2A) . To confirm the CYP2A6 inhibitory activity of decursinol angelate, the nicotine C-oxidase activity was also examined, with the same pattern of CYP2A6 inhibition observed (Fig. 2B) . Further experiments were subsequently carried out to characterize the nature of the inhibition of CYP2A6 by decursinol angelate.
Inactivation of CYP2A6. When preincubated with NADPH-fortified human liver microsomes, decursinol angelate exhibited a significantly increased inhibitory effect on the CYP2A6 activity. For further understanding, a kinetic study of the inhibition was performed with decursinol angelate on human liver microsomes and recombinant CYP2A6. The decrease in the CYP2A6 activity by decursinol angelate was NADPH-, time-, and concentration-dependent and exhibited a pseudo-first-order kinetic pattern (Fig. 3) . The maximal rates (k inact ) and apparent K I values were calculated to be 0.136 min Ϫ1 and 0.99 M in human liver microsomes and 0.054 min Ϫ1 and 2.42 M in recombinant CYP2A6, respectively.
Partition Ratio. The partition ratio (molar ratio of decursinol angelate metabolized per CYP2A6 inactivated) was estimated using the titration method, after incubating the CYP2A6 for 30 min with various concentrations of decursinol angelate to ensure completion of inactivation. On the basis of the titration method, the turnover number was estimated to be ϳ40, resulting in a partition ratio estimate of ϳ39 (Fig. 4) .
Effect of Trapping Agents, Dialysis, and Competitive Inhibitors on CYP2A6 Inactivation. Several attempts were made to reverse the inactivation of CYP2A6 by decursinol angelate. Nucleophilic trapping agents (GSH, NAC, and MOA) and an oxygen scavenging agent (catalase) had no significant effects on the decursinol angelate-medi- 
FIG. 2. The inhibitory effect of decursinol
angelate on the activity of human CYP2A6. The coumarin 7-hydroxylase (A) and nicotine C-oxidase (B) activities were determined following incubation of decursinol angelate in human liver microsomes, with (E) or without the preincubation process (F). Enzyme activities are expressed as a percentage of the control activity. Each data point represents the mean of duplicate determinations.
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at ASPET Journals on April 19, 2017 dmd.aspetjournals.org ated inactivation of CYP2A6, suggesting that any reactive intermediate formed could not be scavenged prior to the enzyme inactivation event, and that the inactivation process was likely confined to the enzyme and did not involve peroxidative reactions outside of the active site. In addition, dialysis had a minimal effect on the CYP2A6 inhibition by decursinol angelate (Fig. 5) .
Pilocarpine, a competitive inhibitor of CYP2A6, diminished the decursinol angelate-mediated inactivation of CYP2A6 in a concentration-dependent manner. The CYP2A6 catalytic activity was recovered to approximately 80% of the control activity by 5 M pilocarpine (Fig. 6) .
Loss of CYP2A6 Spectral Content. The loss of P450 spectral content was not significantly noted when decursinol angelate was incubated with microsomes (data not shown). These results were expected because the CYP2A6 protein content was known to be less than 10% of the total P450 protein in human liver. To ensure a decrease in the spectrally detectable P450 accompanying the decreased enzyme activity, the effect of decursinol angelate on spectral P450 was determined using recombinant CYP2A6. The loss of the P450 spectral content was time and concentration-dependent (data not shown). After 10 min of incubation, approximately 70% of the P450 spectral content was observed in the absence of decursinol angelate, whereas 58 and 36% of the spectrally detectable P450 remained with 5 and 20 M decursinol angelate, respectively (Fig. 7) . 
Metabolism of Decursinol Angelate and Trapping Reactive
Intermediate. The in vitro incubation of decursinol angelate with expressed CYP2A6 demonstrated that decursinol angelate was transformed to five metabolites (Fig. 8) , the structures of which were characterized based on a product ion mass analysis. Metabolites M2, M3, M4, and M5 were identified as monohydroxylated isobaric metabolites, with [MϩH] ϩ ions at m/z 345 (329 ϩ 16); their fragment ions are summarized in Table 1 . Metabolite M1 produced the [MϩH] ϩ ion at m/z 363, which gained 34 Da from that of protonated decursinol angelate; its product ions were at m/z 247, 229, 201, and 187. This metabolite was postulated to be a dihydrodiol derivative. The product ions at m/z 247 and 229 strongly indicated that metabolic modification had taken place on the butenyl moiety of the angeloyl group (Fig. 9) . To examine whether the dihydrodiol metabolite was generated via an epoxide intermediate, GSH and hepatic cytosol, as a source of GSH S-transferase, were added to the incubation mixtures. A new peak, with the [MϩH] ϩ ion at m/z 652, was observed in the full-scan mass chromatogram and constant neutral loss scan of 129, indicating a GSH adduct (Fig. 8) . The m/z 652 ion corresponds to the mass of oxygenated decursinol angelate conjugated with one molecule of GSH and also showed common fragment peaks of decursinol angelate metabolites at m/z 247 and 229 (Table 1 ). The addition of GSH to the incubation mixture resulted in a decrease of the M1 (dihydrodiol metabolite) signal at m/z 363 (data not shown). This finding suggests that GSH trapped the decursinol angelate epoxide intermediate during the metabolism of decursinol angelate toward M1.
Discussion
The modulation of P450s would be important in a clinical view as these enzymes can activate or inactivate a wide range of xenobiotics, including therapeutic agents. CYP2A6 is mainly responsible for the activation of tobacco-related nitrosamines (Tiano et al., 1994; Smith et al., 1995) , and its activity is known to be closely associated with the incidence of tobacco-related cancer (Bartsch et al., 2000) . Pharmacogenomic studies have suggested that male smokers completely lacking CYP2A6 were more resistant to lung cancer (Ariyoshi et al., 2002) . In addition, inhibition of CYP2A6-mediated metabolism would lead to slower elimination of nicotine from the bodies of smokers and, consequently, to a decrease in the number of cigarettes needed to maintain a constant level of nicotine in the body. This decrease in smoking would decrease the exposure to carcinogenic nitrosamines.
The inhibition of the CYP2A6-catalyzed coumarin 7-hydroxylase and nicotine C-oxidase activities by decursinol angelate was dependent on the preincubation process, suggesting that decursinol angelate was a mechanism-based inactivator of CYP2A6. The time-and concentration-dependent inactivation of CYP2A6 by decursinol angelate was readily apparent from a plot of the rate data. The kinetic study exhibited a pseudo-first-order kinetic pattern in both human liver microsomes and recombinant CYP2A6 systems, consistent with the hypothesis that Angelica coumarins inactivate the CYP2A6 enzyme in a mechanism-based action. The K I and k inact values of decursinol angelate were a little different between the hepatic microsomes and recombinant CYP2A6. This was probably because of the interference of other P450 isozyme(s) in the microsomes or a lower efficiency of the recombinant CYP2A6. The partition ratio for CYP2A6 inactivation by decursinol angelate was ϳ39, which is comparable with that by furanocoumarins, well known CYP2A6 inactivators (Koenigs and Trager, 1998) .
The inhibitory reaction by decursinol angelate was NADPH-dependent, and not prevented by the addition of various nucleophiles or reactive oxygen species scavengers. Extensive dialysis exerted a minimal effect on the recovery of the enzyme activity. However, the 577, 523, 506, 459, 353, 261, 247, 229 * GSH (5 mM) and rat liver cytosol (1 mg/ml) were additionally added to the incubation mixture, and the reactions were continued for 60 min at 37°C. The reactions were terminated and analyzed by LC/MS/MS.
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at ASPET Journals on April 19, 2017 dmd.aspetjournals.org addition of pilocarpine, a CYP2A6 competitive inhibitor, was able to prevent CYP2A6 inactivation (Fig. 6) . These results suggest that the inactivation required catalytic processing by CYP2A6, the inactivating event is confined to the active site of the enzyme, the inactivatorenzyme complex is not readily reversible, and the inactivation is not a consequence of a reaction with the reactive oxygen species generated by uncoupling of P450. Furthermore, the loss of the catalytic activity of CYP2A6 was accompanied by a corresponding loss in the spectral content, which is consistent with a general feature of mechanism-based inactivation.
Furanocoumarins, benzyl and phenethyl isothiocyanate, and nicotine analogs have been reported to be inhibitors of CYP2A6 (Koenigs and Trager, 1998; Denton et al., 2004 Denton et al., , 2005 von Weymarn et al., 2006) . Of these, furanocoumarins, such as 8-methoxypsoralen, are well accepted and characterized as CYP2A6 inactivators (Koenigs et al., 1997; Koenigs and Trager, 1998) . 8-Methoxypsoralen is oxidized to the furanoepoxide by CYP2A6, which then reacts with a nucleophilic amino acid at the active site of CYP2A6 to inactivate the enzyme or is hydrolyzed to form a dihydrodiol (Koenigs et al., 1997; Koenigs and Trager, 1998) . However, decursinol angelate has a slightly different chemical structure from that of furanocoumarins and thus would have a different pathway for CYP2A6 inactivation from that of furanocoumarins. In our preliminary study with several pyranocoumarins from A. gigas, decursin and 7-demethylsuberosin also exhibited CYP2A6 inhibitory activity in a similar manner to that of decursinol angelate, but decursinol showed no inhibitory effect (data not shown). Decursinol angelate, decursin, and 7-demethylsuberosin have a common structural feature, possessing an angeloyl group in addition to the pyranocoumarin backbone. The lack of activity in decursinol revealed that the pyranocoumarin moiety was not directly related to the enzyme inactivation but that the metabolism at the butenyl moiety of the angeloyl group might be responsible for the inactivation of CYP2A6. The in vitro incubation of decursinol angelate with recombinant CYP2A6 in the presence of NADPH resulted in the formation of a dihydrodiol derivative, which was presumably generated via an epoxide derivative, as directed in Scheme 1. The intermediacy of an epoxide was supported by the finding that the inclusion of GSH in the incubation mixture generated a conjugate having MS/MS characteristics consistent with the addition of GSH plus a hydroxyl group. Taken together, these results suggest the possibility that CYP2A6 might be inactivated by the reaction with the epoxide at angeloyl moiety generated by the CYP2A6-mediated metabolism of decursinol angelate (Scheme 1). Further investigation using FT-MS is in progress to characterize the decursinol angelate and CYP2A6 isozyme complex.
Coumarin compounds, including decursinol angelate, are major components of A. gigas root; consequently, the effect of a 70% ethanol extract of A. gigas root on the P450 activity was examined. The resulting data showed that A. gigas extract inhibited the coumarin 7-hydroxyase activity of P450 in the same manner as decursinol angelate, with an IC 50 value of approximately 70 g/ml. A. gigas root extract is popularly used as a health supplement for women's care in Europe and America as well as Asia. Therefore, there is a need to consider whether the intake of A. gigas root extract may affect CYP2A6-mediated metabolism. An in vivo study should be undertaken to further understand this process.
In conclusion, our presented data indicated that decursinol angelate, and the related Angelica coumarins, inactivated CYP2A6 in a mechanism-based manner. It is notable that decursinol angelate has a different chemical structure from the other reported CYP2A6 inactivators. These results suggest that Angelica coumarin derivatives, including decursinol angelate or the extract of A. gigas roots, could exert chemopreventive effects against CYP2A6-related cancer.
